

**Can't Stop, Won't Stop the Search for Relief: Scratching the Surface of Itch &
Inflammation in Moderate-to-Severe Atopic Dermatitis
Tweetorial #3 Reference List**

Tweet #2:

Renert-Yuval Y, Guttman-Yassky E. *Ann Allergy Asthma Immunol.* 2020;124(1):28-35.

Tweet #3:

Gibbs BF, Patsinakidis N, Raap U. Role of the pruritic cytokine IL-31 in autoimmune skin diseases. *Front Immunol.* 2019;10:1383.

Tweet #5:

Nakagawa H, Nemoto O, Igarashi A, Nagata T. Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study. *Br J Dermatol.* 2018;178(2):424-432.

Tweet #6:

Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet.* 2020 Jul;396(10246):255-266.

Pfizer, Inc. Pfizer Announced Positive Top-Line Results From Second Pivotal Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib, in Patients Aged 12 and Older With Moderate to Severe Atopic Dermatitis. Pfizer website. September 2019. Accessed September 13, 2020.

<https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-from-second-pivotal-phase-3-study-of-investigational-oral-jak1-candidate-abrocitinib-in-patients-aged-12-and-older-with-moderate-to-severe-atopic-dermatitis/>

Pfizer, Inc. Pfizer Announces Positive Top-Line Results From Third Phase 3 Trial Of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch. Pfizer Website. March 2020. Accessed September 13, 2020.

<https://investors.pfizer.com/investor-news/press-release-details/2020/Pfizer-Announces-Positive-Top-Line-Results-from-Third-Phase-3-Trial-of-Abrocitinib-for-Moderate-to-Severe-Atopic-Dermatitis-Which-Showed-Improvements-in-Skin-Clearance-Disease-Extent-and-Severity-and-Itch/default.aspx>

Pfizer announces positive top-line results from JADE TEEN trial of abrocitinib in adolescents with moderate-to-severe atopic dermatitis. *Pharmaceutical Business Review.* Jun 11, 2020. Accessed September 13, 2020. <https://www.pharmaceutical-business-review.com/news/pfizer-announces-positive-top-line-results-from-jade-teen-trial-of-abrocitinib-in-adolescents-with-moderate-to-severe-atopic-dermatitis/>

Tweet #7:

Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet*. 2020 Jul;396(10246):255-266.

Pfizer, Inc. Pfizer Announced Positive Top-Line Results From Second Pivotal Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib, in Patients Aged 12 and Older With Moderate to Severe Atopic Dermatitis. Pfizer website. September 2019. Accessed September 13, 2020.

<https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-from-second-pivotal-phase-3-study-of-investigational-oral-jak1-candidate-abrocitinib-in-patients-aged-12-and-older-with-moderate-to-severe-atopic-dermatitis/>

Pfizer, Inc. Pfizer Announces Positive Top-Line Results From Third Phase 3 Trial Of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch. Pfizer Website. March 2020. Accessed September 13, 2020.

<https://investors.pfizer.com/investor-news/press-release-details/2020/Pfizer-Announces-Positive-Top-Line-Results-from-Third-Phase-3-Trial-of-Abrocitinib-for-Moderate-to-Severe-Atopic-Dermatitis-Which-Showed-Improvements-in-Skin-Clearance-Disease-Extent-and-Severity-and-Itch/default.aspx/>

Tweet #8:

Pfizer, Inc. PFIZER ANNOUNCES POSITIVE RESULTS FROM FIFTH PHASE 3 TRIAL OF ABROCITINIB, EVALUATING SAFETY AND EFFICACY ACROSS DIFFERENT DOSING REGIMENS. Pfizer Website. November 2020. Accessed April 22, 2020. <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-results-fifth-phase-3-trial>.

Tweet #9:

AbbVie, Inc. RINVOQ™ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis. AbbVie Website. December 2020. Accessed April 22, 2020. <https://news.abbvie.com/news/press-releases/rinvoq-upadacitinib-achieved-superiority-versus-dupixent-dupilumab-for-primary-and-all-ranked-secondary-endpoints-in-phase-3b-head-to-head-study-in-adults-with-atopic-dermatitis.htm>

Tweet #10:

AbbVie Inc. Third Pivotal Phase 3 Study Shows RINVOQ™ (Upadacitinib) Plus Topical Corticosteroids Improves Skin and Itch Symptoms in Atopic Dermatitis Patients. AbbVie website. July 28, 2020. Accessed September 13, 2020. <https://news.abbvie.com/news/press-releases/third-pivotal-phase-3-study-shows-rinvoq-upadacitinib-plus-topical-corticosteroids-improves-skin-and-itch-symptoms-in-atopic-dermatitis-patients.htm>

Tweet #11:

AbbVie Inc. Third Pivotal Phase 3 Study Shows RINVOQ™ (Upadacitinib) Plus Topical Corticosteroids Improves Skin and Itch Symptoms in Atopic Dermatitis Patients. AbbVie website. July 28, 2020. Accessed September 13, 2020. <https://news.abbvie.com/news/press-releases/third-pivotal-phase-3-study-shows-rinvoq-upadacitinib-plus-topical-corticosteroids-improves-skin-and-itch-symptoms-in-atopic-dermatitis-patients.htm>

Tweet #12:

Eli Lilly and Company. Lilly And Incyte Announce Positive Top-Line Results From The North American (BREEZE-AD5) Phase 3 Study of Oral Selective JAK Inhibitor Baricitinib in Patients With Moderate to Severe Atopic Dermatitis. Eli Lilly website. January 30, 2020. Accessed September 13, 2020.

<https://investor.lilly.com/news-releases/news-release-details/lilly-and-incyte-announce-positive-top-line-results-north/>

Tweet 13:

Eli Lilly and Company. EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis. Lilly Website. October 2020. Accessed April 22, 2021.

<https://investor.lilly.com/news-releases/news-release-details/eadv-2020-lilly-and-incyte-showcase-new-data-baricitinib>.

Tweet 14:

Reich K, Kabashima K, Peris K, et al. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial. *JAMA Dermatol*. 2020;156(12):1333–1343. doi:10.1001/jamadermatol.2020.3260